BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23020826)

  • 1. Refractory neuro-Behçet treated by tocilizumab: a case report.
    Urbaniak P; Hasler P; Kretzschmar S
    Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody.
    Chen J; Chen S; He J
    Clin Exp Rheumatol; 2017; 35 Suppl 108(6):116-118. PubMed ID: 28980896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical presentation of Behçet's disease with central nervous system involvement successfully treated with infliximab.
    Studer U; Ruehe B; Waldegg G; Vajtai I; Escher R; Aeberli D
    Rheumatol Int; 2012 May; 32(5):1431-5. PubMed ID: 21445544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Hirano T; Ohguro N; Hohki S; Hagihara K; Shima Y; Narazaki M; Ogata A; Yoshizaki K; Kumanogoh A; Kishimoto T; Tanaka T
    Mod Rheumatol; 2012 Apr; 22(2):298-302. PubMed ID: 21748365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological complications of Behçet's syndrome.
    Kidd D
    Curr Neurol Neurosci Rep; 2012 Dec; 12(6):675-9. PubMed ID: 23007835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
    Sarwar H; McGrath H; Espinoza LR
    J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
    Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
    Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
    J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Infliximab treatment trial in a patient with neuro-Behçet's disease unresponsive to other treatments].
    Kadowaki S; Matsuda N; Moriya A; Ebitani M; Yoshihara A; Nakamura K; Mochizuki H; Ugawa Y
    Rinsho Shinkeigaku; 2011 Apr; 51(4):261-6. PubMed ID: 21595295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
    Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
    [No Abstract]   [Full Text] [Related]  

  • 12. Infliximab therapy in parenchymal neuro-Behçet's disease: A single-center experience.
    Yalcin Kehribar D; Gunaydin S; Ozgen M
    Int J Rheum Dis; 2021 Oct; 24(10):1302-1307. PubMed ID: 34427044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
    Morris DS; Gavin MP; Sturrock RD
    Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.
    Fujikawa K; Aratake K; Kawakami A; Aramaki T; Iwanaga N; Izumi Y; Arima K; Kamachi M; Tamai M; Huang M; Nakamura H; Nishiura Y; Origuchi T; Ida H; Eguchi K
    Ann Rheum Dis; 2007 Jan; 66(1):136-7. PubMed ID: 17178762
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
    Olivieri I; D' Angelo S; Padula A; Leccese P; Mennillo GA
    Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of infliximab in progressive neuro-Behçet's syndrome.
    Kikuchi H; Aramaki K; Hirohata S
    J Neurol Sci; 2008 Sep; 272(1-2):99-105. PubMed ID: 18550081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
    Belzunegui J; López L; Paniagua I; Intxausti JJ; Maíz O
    Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
    [No Abstract]   [Full Text] [Related]  

  • 18. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
    Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
    Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
    Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
    Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
    Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.